05 May
2022
16:00 E.S.T.

Calyxt, Inc., Cellectis’ Majority-Owned Subsidiary, Reports Its First Quarter 2022 Financial Results

Read more

28 Apr
2022
08:00 E.S.T.

Cellectis Publishes Two Articles in Nature Communications Providing Strong Preclinical Validation of UCART123 to Treat AML and BPDCN

Read more

27 Apr
2022
04:00 E.S.T.

Cellectis Receives $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics

Read more

08 Apr
2022
16:30 E.S.T.

Cellectis Presents Preclinical Data from its First Allogeneic Dual CAR T-cell Product Candidate UCART20x22 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Read more

11 Mar
2022
13:15 E.S.T.

Cellectis to Participate in Two Upcoming Investor Conferences in March

Read more

03 Mar
2022
13:46 E.S.T.

Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2021 Financial Results

Read more

24 Feb
2022
13:13 E.S.T.

Cellectis to Hold Fourth Quarter 2021 Earnings Call on Friday March 4, 2022 at 8:00AM EST

Read more

18 Feb
2022
15:22 E.S.T.

Calyxt Announces Pricing of Offering of Common Stock and Warrants and Updates Business and Risk Factor Disclosure

Read more

10 Feb
2022
16:44 E.S.T.

Cellectis Appoints Bing Wang, PhD, MBA as Chief Financial Officer

Read more

10 Jan
2022
16:30 E.S.T.

Cellectis’ Licensed Partner, Allogene Therapeutics,  Announces Removal of FDA Clinical Hold on their Clinical Trials

Read more